Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript Summary
Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript:
以下是Knight Therapeutics Inc.(KHTRF)2024年第三季度業績會議電話交易摘要:
Financial Performance:
財務表現:
Q3 revenue reached $91 million, a 12% increase year-over-year, with a constant currency basis increase of 18%.
Adjusted EBITDA was $13.5 million, down 13% from the previous year, with adjusted EBITDA per share at $0.13, a decrease of 10%.
Gross margin was reported at 47%, down from 52% the previous year, primarily due to product mix, including a higher proportion of AmBisome sales to the Ministry of Health.
Operating expenses excluding amortization of non-current assets increased by 11% to $30.5 million, driven by marketing spends for new product launches and increases in R&D and G&A costs.
第三季度營業收入達到9100萬美元,同比增長12%,按固定匯率基礎增長18%。
調整後的EBITDA爲1350萬美元,比去年同期下降13%,每股調整後的EBITDA爲0.13美元,下降10%。
毛利率報告爲47%,低於上一年的52%,主要是由於產品組合的變化,包括向衛生部銷售AmBisome比例增加。
不包括非流動資產攤銷的營業費用增加了11%,達到3050萬美元,主要是由於新產品推出的市場支出以及研發和管理費用增加。
Business Progress:
業務進展:
Launched NCIB, purchasing 437,500 common shares at an average price of $5.65.
Advanced the pipeline with regulatory approval of Minjuvi in Mexico, expecting launch in first half of 2025.
Delivered record nine-month revenues of over $271 million and adjusted EBITDA of over $42 million, driven by promoted portfolio growth and recent product launches in Canada and Brazil.
推出NCIb,以平均價格5.65美元購買了437,500股普通股。
通過墨西哥Minjuvi的監管批准,預計將於2025年上半年推出。
實現超過27100萬美元的創紀錄的九個月營業收入,並實現超過4200萬美元的調整後的EBITDA,受促進的投資組合增長和加拿大和巴西最近產品推出的推動。
Opportunities:
機會:
Continue to drive growth through Knight's innovative promoted portfolio, including recent launches and expected regulatory approvals, targeting a combined potential revenue of over $150 million.
繼續通過Knight創新的推廣投資組合推動增長,包括最近推出和預期的監管批准,旨在實現超過15000萬美元的潛在總收入。
Risks:
風險:
Market and currency fluctuations impacting revenue growth and profitability, particularly noted in currency depreciation from Q1 to Q3 2024 affecting LatAm financial results.
Potential generic entry for Lenvima leading to a gradual revenue decline over several years.
市場和貨幣波動影響營業收入增長和盈利能力,尤其是2024年第一季度至第三季度貨幣貶值影響LatAm財務結果。
Lenvima潛在的仿製藥進入導致在未來幾年逐漸下降的營收。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。